![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/01/30/2820140/0/en/Kairos-Pharma-Doses-First-Patient-in-Phase-2-Trial-of-Lead-Drug-Candidate-ENV105-with-Apalutamide-to-Improve-Therapy-Sensitivity-for-Castrate-Resistant-Prostate-Cancer.html
https://www.globenewswire.com//news-release/2024/01/16/2810031/0/en/Kairos-Pharma-Doses-First-Patients-in-Phase-1-Trial-of-Lead-Drug-Candidate-ENV105-with-Osimertinib-to-Improve-Therapy-Sensitivity-for-EGFR-Driven-Lung-Cancer.html
https://www.clinicaltrialsarena.com/news/kairos-trial-glioblastoma-therapy/
https://www.prnewswire.com/news-releases/kairos-pharma-receives-fda-approval-of-investigational-new-drug-ind-application-for-its-phase-1-clinical-trial-of-kros-201-for-the-treatment-of-glioblastoma-announces-new-patent-for-kros-401-301502125.html